AMRI makes a promotion in Singapore

Takeshi Yura becomes senior director of drug discovery services

Takeshi Yura has been promoted to senior director of drug discovery services at AMRI’s Singapore subsidiary.

In this expanded role, Yura will take overall responsibility for site management, which includes leadership of the AMRI Singapore Research Centre's chemistry, biology and r&d operations.

Yura will replace Raymond Yeung, who has been managing director of the site from 2007.

Initially joining the Singapore subsidiary in January as assistant director of medicinal chemistry, Yura has more than 22 years of experience in discovery chemistry, project management and business development.

Prior to joining AMRI, he was a director at Dishman Japan, responsible for sales and business development activities. Before this he was discovery chemistry research head at Pfizer Japan, and section head of medicinal chemistry at Bayer Yakuhin.

‘Since joining us earlier this year, we have been impressed with the extent of scientific and business leadership Dr Yura has brought to AMRI and look forward to the additional contributions he will bring to the company in this new role,’ said Bruce Sargent, senior vp of drug discovery at AMRI.

You may also like

Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Research & Development

SPARK THE MIDLANDS backs Aston University anti-cancer bone paste collaboration

A collaboration between Aston University and Royal Orthopaedic Hospital NHS Foundation Trust has secured support from SPARK THE MIDLANDS to advance a minimally invasive gallium-doped injectable paste for treating primary and metastatic bone cancer
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Landmark NHS‑Galleri trial cuts Stage IV cancers and boosts early detection across England

NHS‑Galleri trial shows multi‑cancer blood test sharply reduces late‑stage diagnoses and boosts early detection—possibly signalling a structural change in cancer drug demand, supply chain planning and long-term oncology production strategy
Research & Development

Horizon Europe 2025 grant backs Phase II trial of HER-096 for Parkinson’s disease

Herantis Pharma has secured selection for €8m in non-dilutive funding under Horizon Europe to advance a Phase II proof-of-concept study of its subcutaneously delivered Parkinson’s therapy candidate HER-096
Subscribe now